CUBO™
Browse all Indena’s documents about products, events, company information and so much more.
Go to section
See through science
CUBO™
Scroll to see more
Peer-reviewed science on CUBO™
The verified winning duo for gut health
A randomized, placebo-controlled study was conducted on 49 adults with an IBS or small bowel dysbiosis diagnosis. All subjects followed a low-FODMAP diet; 24 of them were also supplemented with a 380-mg tablet of CUBO™, twice a day, while the rest formed a control group and received a placebo.1
After 30 days of admininistration, the study showed a significant bloating control in the supplemented group (-83%, p<0.0001), as assessed using a 4-score questionnaire (Figure 1). Moreover, authors highlighted a relevant beneficial effect in abdominal discomfort control (Figure 2) and in intestinal dysbiosis markers (Figure 3). Overall, the global assessment of efficacy (GAE) showed that 91.6% of supplemented subjects reported a high efficacy (Figure 4).1
Figure 1: Graphical representation of the bloating intensity modulation in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age.
Figure 2: Graphical representation of the abdominal discomfort modulation in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age.
Figure 3: Graphical representation of urinary markers for intestinal dysbiosis in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age. Levels of a metabolic product, resulting from bacterial action on tryptophan in the small bowel, were used as a marker of dysbiosis and malabsorption.
Figure 4: Graphical representation of the Global Assessment of Efficacy (GAE) in control and supplemented groups after 30 days.
BIBLIOGRAPHY
1. Data to be published.
